Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
DiaComp Funded Abstracts
Pilot & Feasibility
Pilot & Feasibility Program Application Abstract
Sarm1 and diabetic complications in adolescents with type 1 diabetes
(Saint Louis, MO)
Pilot & Feasibility Program
In America, there are 1.6 million people living with type 1 diabetes (T1D), including nearly 200,000 children and adolescents. Young adults with T1D often have difficulty maintaining adequate glycemic control relative to other age groups, putting them at increased risk for early development of diabetic complications in systems including nerve and bone. Therapies that can be used to simultaneously prevent or to reverse multiple diabetic complications during times of glycemic instability, beginning in childhood and adolescence and continuing throughout the lifespan, are needed to promote lifelong health and healthy aging in patients with T1D. Sarm1 (sterile a and TIR motif-containing protein-1) is homomultimeric cytoplasmic protein with NADase and ADP-ribosyl cyclase activity. Sarm1 is a metabolic biosensor that is activated by injury, inflammation, and oxidative stress. When activated, Sarm1 promotes the progression of diabetic peripheral neuropathy. In addition, we have recently discovered that Sarm1 drives bone loss and skeletal instability in mice with T1D. Progression of DPN often tracks with fracture risk, suggesting shared underlying mechanisms of development and/or direct relationships between nerve and bone health. In humans, as in mice, we hypothesize that increases in Sarm1 expression and activation occur in adolescents with poorly controlled T1D in response to inadequate glycemic control, contributing to the early onset and progression of diabetic complications in nerve and bone. To test this hypothesis while obtaining foundational preliminary data for future longitudinal studies, we will pursue two specific aims. First, we will quantify Sarm1 expression and activation in adolescents with T1D relative to non-diabetic controls. Second, we will explore the relationship between Sarm1, neuropathy, and bone quality. This is timely because Sarm1 inhibitors are currently in preclinical development for treatment of peripheral nerve damage. Our goal is to define young patients with T1D that may benefit from future use of Sarm1 inhibitors as a clinical strategy to prevent diabetic complications across multiple systems including nerve and bone.
Data for this report has not yet been released.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!